A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy

Kidney International

Volumn 78, Issue 3, 2010, Pages 257-268

  Pang, Maoyin ^a   Ma, Li ^b   Gong, Rujun ^a   Tolbert, Evelyn ^a   Mao, Haiping ^c   Ponnusamy, Murugavel ^a   Chin, Y Eugene ^b   Yan, Haidong ^d   Dworkin, Lance D ^a   Zhuang, Shougang ^a  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

^d TONGJI UNIVERSITY   (China)

Author keywords

chronic kidney disease; renal interstitial fibroblasts; STAT3; transforming growth factor; unilateral ureteral obstruction

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CYTOKINE; FIBRONECTIN; PROTEIN INHIBITOR; S3I 201; SCLEROPROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ATTENUATION; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; EXTRACELLULAR MATRIX; FIBROBLAST; INFLAMMATORY CELL; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY INTERSTITIUM; MALE; MEDIATOR; MOUSE; NONHUMAN; OBSTRUCTIVE NEPHROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; URETER OBSTRUCTION;

EID: 77954730368     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.154     Document Type: Article

References (48)

1. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210.
2. Neilson EG. Mechanisms of disease: fibroblasts-a new look at an old problem. Nat Clin Pract Nephrol 2006;2: 101-108.
3. Grande MT, Lopez-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 2009;5: 319-328.
4. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006;69: 213-217.
5. Negri AL. Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents. J Nephrol 2004;17: 496-503.
6. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 2004;82: 175-181.
7. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18: 816-827.
8. Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007;87: 1077-1091.
9. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002;13: 2600-2610.
10. Misseri R, Rink RC, Meldrum DR , et al. Inflammatory mediators and growth factors in obstructive renal injury. J Surg Res 2004;119: 149-159.
11. Bani-Hani AH, Campbell MT, Meldrum DR , et al. Cytokines in epithelial- mesenchymal transition: a new insight into obstructive nephropathy. J Urol 2008;180: 461-468.
12. Taal MW, Zandi-Nejad K, Weening B , et al. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int 2000;58: 1664-1676.
13. Horvath CM. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci 2000; 25: 496-502.
14. Fuller GM, Zhang Z. Transcriptional control mechanism of fibrinogen gene expression. Ann N Y Acad Sci 2001;936: 469-479.
15. Ogata H, Chinen T, Yoshida T , et al. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 2006; 25: 2520-2530.
16. Stepkowski SM, Chen W, Ross JA , et al. STAT3: an important regulator of multiple cytokine functions. Transplantation 2008;85: 1372-1377.
17. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19: 6613-6626.
18. Yamamoto T, Matsuda T, Muraguchi A , et al. Cross-talk between IL-6 and TGF-beta signaling in hepatoma cells. FEBS Lett 2001;492: 247-253.
19. VijN, Sharma A, Thakkar M , et al. PDGF-driven proliferation, migration, and IL8 chemokine secretion in human corneal fibroblasts involve JAK2- STAT3 signaling pathway. Mol Vis 2008;14: 1020-1027.
20. Wang YZ, Wharton W, Garcia R , et al. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity. Oncogene 2000;19: 2075-2085.
21. Kretzschmar AK, Dinger MC, Henze C , et al. Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells. Biochem J 2004;377: 289-297.
22. Lim CP, Phan TT, Lim IJ , et al. Cytokine profiling and Stat3 phosphorylation in epithelial-mesenchymal interactions between keloid keratinocytes and fibroblasts. J Invest Dermatol 2009;129: 851-861.
23. Kuratsune M, Masaki T, Hirai T , et al. Signal transducer and activator of transcription 3 involvement in the development of renal interstitial fibrosis after unilateral ureteral obstruction. Nephrology (Carlton) 2007; 12: 565-571.
24. Siddiquee K, Zhang S, Guida WC , et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007;104: 7391-7396.
25. Aaronson DS, Horvath CM. A road map for those who don't know JAK- STAT. Science 2002;296: 1653-1655.
26. Wen Z, Zhong Z, Darnell Jr JE. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995; 82: 241-250.
27. Hosui A, Kimura A, Yamaji D , et al. Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-\{beta\} and STAT3 activation. J Exp Med 2009;206: 819-831.
28. Walters DM, Antao-Menezes A, Ingram JL , et al. Susceptibility of signal transducer and activator of transcription-1-deficient mice to pulmonary fibrogenesis. Am J Pathol 2005;167: 1221-1229.
29. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009;75: 1145-1152.
30. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007;292: F905-F911.
31. Jiang YG, Luo Y, He DL , et al. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. Int J Urol 2007;14: 1034-1039.
32. Zidar N, Gale N, Kojc N , et al. Cadherin-catenin complex and transcription factor Snail-1 in spindle cell carcinoma of the head and neck. Virchows Arch 2008;453: 267-274.
33. Colman H, Giannini C, Huang L , et al. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol 2006; 30: 657-664.
34. Lee K, Song K. Basal c-Jun N-terminal kinases promote mitotic progression through histone H3 phosphorylation. Cell Cycle 2008;7: 216-221.
35. Lane A, Johnson DW, Pat B , et al. Interacting roles of myofibroblasts, apoptosis and fibrogenic growth factors in the pathogenesis of renal tubulo-interstitial fibrosis. Growth Factors 2002;20: 109-119.
36. Vesey DA, Cheung CW, Cuttle L , et al. Interleukin-1beta induces human proximal tubule cell injury, alpha-smooth muscle actin expression and fibronectin production. Kidney Int 2002;62: 31-40.
37. Arakawa T, Masaki T, Hirai T , et al. Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis. Nephrol Dial Transplant 2008;23: 3418-3426.
38. Berthier CC, Zhang H, Schin M , et al. Enhanced expression of Janus kinase- signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 2009; 58: 469-477.
39. Herrmann JE, Imura T, Song B , et al. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci 2008; 28: 7231-7243.
40. Baggiolini M, Loetscher P, Moser B. Interleukin-8 and the chemokine family. Int J Immunopharmacol 1995;17: 103-108.
41. Lloyd CM, Minto AW, Dorf ME , et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997;185: 1371-1380.
42. Chow FY, Nikolic-Paterson DJ, Ozols E , et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80.
43. Meydan N, Grunberger T, Dadi H , et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996;379: 645-648.
44. Wang LH, Kirken RA, Erwin RA , et al. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J Immunol 1999;162: 3897-3904.
45. Ishihara K, Satoh I, Mue S , et al. Possible participation of a JAK2 signaling pathway in recombinant rat interleukin-5-induced prolongation of rat eosinophil survival. Biochim Biophys Acta 2001;1536: 73-84.
46. Chevalier RL. Obstructive nephropathy: towards biomarker discovery and gene therapy. Nat Clin Pract Nephrol 2006;2: 157-168.
47. Pang M, Kothapally J, Mao H , et al. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2009;297: F996-F1005.
48. Gong R, Ge Y, Chen S , et al. Glycogen synthase kinase 3beta: a novel marker and modulator of inflammatory injury in chronic renal allograft disease. Am J Transplant 2008;8: 1852-1863.